|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-10-12
|
|
pubmed:abstractText |
Trimethoprim/sulfamethoxazole (T/S) is an essential drug in patients with human immunodeficiency virus type-1 (HIV-1) infection to prevent opportunistic infections. About 40% to 60% of them develop skin rash which leads to discontinue the medication. A precise mechanism of the reaction is not known.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1081-1206
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
241-4
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11030281-Administration, Oral,
pubmed-meshheading:11030281-Adolescent,
pubmed-meshheading:11030281-Adult,
pubmed-meshheading:11030281-CD4-Positive T-Lymphocytes,
pubmed-meshheading:11030281-Desensitization, Immunologic,
pubmed-meshheading:11030281-Drug Tolerance,
pubmed-meshheading:11030281-Female,
pubmed-meshheading:11030281-HIV Infections,
pubmed-meshheading:11030281-HIV-1,
pubmed-meshheading:11030281-Humans,
pubmed-meshheading:11030281-Immunoglobulin E,
pubmed-meshheading:11030281-Lymphocyte Count,
pubmed-meshheading:11030281-Male,
pubmed-meshheading:11030281-Middle Aged,
pubmed-meshheading:11030281-Time Factors,
pubmed-meshheading:11030281-Trimethoprim-Sulfamethoxazole Combination
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S.
|
|
pubmed:affiliation |
AIDS Clinical Center, International Medical Center of Japan, Tokyo.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
